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Introduction: Until now, there are several reports on cutaneous manifestations in
COVID-19 patients. However, the link between skin manifestations and the severity of the
disease remains debatable. We conducted a systematic review to evaluate the temporal
relationship between different types of skin lesions and the severity of COVID-19.
Methods: A systematic search was conducted for relevant studies published between
January and July 2020 using Pubmed/Medline, Embase, and Web of knowledge. The
following keywords were used: “SARS-CoV-2” or “COVID-19” or “new coronavirus”
or “Wuhan Coronavirus” or “coronavirus disease 2019” and “skin disease” or “skin
manifestation” or “cutaneous manifestation.”
Results: Out of 381 articles, 47 meet the inclusion criteria and a total of 1,847
patients with confirmed COVID-19 were examined. The overall frequency of cutaneous
manifestations in COVID-19 patients was 5.95%. The maculopapular rash was the
main reported skin involvement (37.3%) commonly occurred in middle-aged females
with intermediate severity of the disease. Forty-eight percentage of the patients had a
mild, 32% a moderate, and 20% a severe COVID-19 disease. The mild disease was
mainly correlated with chilblain-like and urticaria-like lesions and patients with vascular
lesions experienced a more severe disease. Seventy-two percentage of patients with
chilblain-like lesions improved without any medication. The overall mortality rate was
4.5%. Patients with vascular lesions had the highest mortality rate (18.2%) and patients
with urticaria-like lesions had the lowest mortality rate (2.2%).
Conclusion: The mere occurrence of skin manifestations in COVID-19 patients is not
an indicator for the disease severity, and it highly depends on the type of skin lesions.
Chilblain-like and vascular lesions are the ends of a spectrum in which from chilblain-like
to vascular lesions, the severity of the disease increases, and the patient’s prognosis
worsens. Those with vascular lesions should also be considered as high-priority patients
for further medical care.
Keywords: COVID-19, coronavirus – COVID-19, skin manifestations, skin - pathology, systematic literature search,
disease severity, mortality, prognosis
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INTRODUCTION

Data Extraction
Data about the first author’s name, date of publication,
country, number of COVID-19 patients, number of cases with
skin manifestations, age, gender, location and type of skin
manifestations, associated cutaneous symptoms, the onset of
skin lesions with systemic symptoms, the median duration of
the lesions, treatment strategies and main histological findings
of the lesions as well as comorbidities, associated symptoms,
drug history, laboratory findings, severity and outcome of
the patients were selected for further analysis. All cutaneous
presentations related to COVID-19 were categorized into six
groups: chilblain-like, vesicular, urticaria-like, maculopapular,
vascular, and miscellaneous (lesions that we couldn’t subscribe
to any of the groups). Petechiae, purpura, livedo, and necrosis
were classified into vascular lesions. Two authors (PJ, BH)
independently extracted the data from the selected studies. The
data was jointly reconciled, and disagreements were discussed
and resolved between review authors (PJ, BH, MJN).

A viral outbreak caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) emerged from Wuhan, China in
late December 2019 (1). The disease was named coronavirus
disease 2019 (COVID-19) by World Health Organization
(WHO) and was declared as a pandemic on 11 March 2020
(2). After 1 year from the beginning of the pandemic, the
full spectrum of COVID-19 presentations and its relationship
with disease severity is still unknown. Fever, cough, chills,
dyspnea, myalgia, and sore throat are the most common clinical
presentations of COVID-19 and as time goes on, different other
manifestations have been reported (3). Recently, skin lesions
have been described as potential manifestations of COVID19 (4–6). The cutaneous changes reported to date include
maculopapular rash, vesicular lesions, urticaria-like lesions, and
chilblain-like lesions (4–8). Some of these skin manifestations
arise before the signs and symptoms more commonly associated
with COVID-19, suggesting that they could be presenting signs
of COVID-19 (9). However, the link between skin manifestations
and the severity of the disease remains debatable. Due to the
great variety of reported dermatologic presentations as well
as the inconsistency of data on the association between skin
presentations of COVID-19 with poor outcome, we aimed to
conduct a comprehensive systematic review on the clinical
and histopathological characteristics of skin manifestations in
relation to other features of confirmed COVID-19 patients and
to evaluate the temporal relationship between different types of
skin lesions and the severity of COVID-19.

Quality Assessment
The critical appraisal checklist for case reports provided by the
Joanna Briggs Institute (JBI) was used to perform a quality
assessment of the studies (11).

RESULTS
At the first round of review, 381 articles were selected. After
removing the duplicates and studies that did not meet the
entry criteria, 88 full texts were finally selected for further
assessment. Of these, only 47 articles had the characteristics
appropriated for systematic review and were entered into the
data extraction (Figure 1). Most of the studies were case reports
(47%, N: 22) followed by case series (42.4%, N: 20), retrospective
hospital/private section-based study (6.4%, N: 3), and crosssectional (4.2%, N: 2). Thirteen articles were originated from
Italy, 11 from Spain, 10 from France, 5 from the USA, and others
from Belgium, China, Thailand, Kuwait, Indonesia, Russia,
Turkey, and Singapore. Information of the 47 analyzed articles
can be found in Table 1.
A total of 1,847 patients with confirmed COVID-19 (based on
positive RT-PCR or positive antibody tests) were examined in 47
articles, of which 597 patients had different skin manifestations.
The overall frequency of cutaneous manifestations in COVID-19
patients was 5.95%.

METHODS
This review conforms to the “Preferred Reporting Items
for Systematic Reviews and Meta-Analyses” (PRISMA)
statement (10). Registration: PROSPERO (pending registration
ID: 215422).

Search Strategy and Selection Criteria
To investigate the prevalence and characteristics of cutaneous
manifestations in COVID-19 patients, a systematic search was
conducted for relevant studies published between January and
July 2020 using Pubmed, Embase, and Web of knowledge.
The following search terms were used (designed using MeSH
keywords and Emtree terms): “SARS-CoV-2” or “COVID-19”
or “new coronavirus” or “Wuhan Coronavirus” or “coronavirus
disease 2019” and “skin disease” or “skin manifestation”
or “cutaneous manifestation.” Only studies included if they
contained data about the skin manifestation in patients with
confirmed COVID-19. There were no language restrictions. We
got help from the Google Translate system for non-English
papers. Review articles, duplicate publications, and articles with
no relevant data were excluded from the analysis. Two authors
independently screened the remaining articles. Finally, selected
data were extracted from the full-texts of eligible publication by
other investigators of the team.

Frontiers in Medicine | www.frontiersin.org

Characteristics of the Cutaneous Lesions
in Confirmed COVID-19 Patients
The maculopapular rash was the main reported skin involvement
(37.3%) followed by chilblain-like lesions (18.4%). The
prevalence rate of vesicular and urticaria-like lesions was
15% (Table 4).
The mean age of patients with cutaneous manifestations was
53.3 (ranging from 16 to 92) years. Chilblain-like lesions were
more common in younger patients (mean age: 40.7 years) and
vascular lesions were more common in the elderly (mean age:
72.3 years).

2

February 2021 | Volume 8 | Article 634208

Jamshidi et al.

Skin Manifestations in COVID-19 Patients

FIGURE 1 | Flow chart of study selection for inclusion in the systematic review and meta-analysis.

(34.5%) with the onset of systemic symptoms of COVID19. Urticaria-like lesions appeared usually as a concomitant
symptom (47%). In 3.5% of patients particularly with chilblainlike lesions, skin manifestations were the only presentation of
COVID-19. In 7% of patients, skin manifestations occurred
before the systemic symptoms, particularly in chilblain-like
lesions (Table 4).
The median duration of skin lesions was about 9 days ranging
from 1 to 18 days (Table 4). Urticaria-like lesions had the least
duration (5 days) and chilblain-like lesions had the most duration
(14 days).
No skin biopsy or histological examination of urticarialike lesions was performed. Therefore, the following results are
related to other types of skin lesions.
Perivascular lymphocytic infiltration, spongiotic and interface
dermatitis, and vacuolization or keratinocyte necrosis were the
common histologic findings in skin biopsies, except for vesicular
lesions. In vesicular lesions, the absence of inflammatory
infiltrates, atrophic epidermis, and hyperkeratosis was reported.
In almost all types of lesions (except maculopapular and
vesicular lesions) thrombotic vasculopathy and red blood
cell extravasation were present. Langerhans cell aggregations

The prevalence of skin lesions was slightly higher in
females than males (54 vs. 46%). Urticaria-like, chilblain- like
and miscellaneous lesions were more frequent among females
(Table 4). Vascular lesions were more frequent in males (61%).
The prevalence of vesicular and maculopapular lesions was
almost the same in men and women (51 and 49%).
Trunk, lower limb, and upper limb were the main involved
regions. Chilblain-like and vascular lesions were more common
in acral areas and except for maculopapular lesions, others were
commonly located in the trunk. The maculopapular lesions were
more common in extremities. The involvement of palms and
soles were rare. Mucous membrane involvement was reported in
all types of skin lesions particularly maculopapular and vascular
lesions, but it was not reported in chilblain-like lesions (Table 4).
Vesicular rashes could have diffused polymorphic or localized
monomorphic patterns (27, 37).
Out of 597, 397 (66%) of the patients had associated
cutaneous symptoms. Pruritus was the most prominent (238,
60%) particularly in vesicular lesions (89%). Pain was the most
frequent symptom in chilblain-like lesions (63.5%) (see Table 4).
In the majority of patients (89.5%), dermatologic
manifestations presented after (55%) or at the same time

Frontiers in Medicine | www.frontiersin.org
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TABLE 1 | Characteristics of the included studies.
First author

Country

Published time

Type of study

Mean age

Male/
Female

Hunt, M. (12)

USA

Mar 28-2020

Case report

*Recalcati, S. (6)

Italy

Apr 7-2020

Retrospective
hospital-based study

*Joob, B. (13)

Thailand

Apr 7-2020

Retrospective
hospital-based study

Zhang, Y. (14)

China

Apr 7-2020

Fiehn, C. (15)

Spain

Apr 15-2020

Mahé, A. (16)

France

Zulfiqar, A. A. (17)
*Magro, C. (18)

No. of confirmed
COVID-19
patient(s)

20

1M

1

1

–

–

88

18

40.5

4 M, 37 F

41

1

Case series

59

4 M, 3 F

7

7

Case report

28

1F

1

1

Apr 16-2020

Case report

46

1F

1

1

France

Apr 16-2020

Case report

65

1F

1

1

USA

Apr 18-2020

Case series

54.6

3 M, 2 F

5

3

Morey-Olive, M. (19)

Spain

Apr 22-2020

Case series

Boy: 6 years
Girl: 2 months

1 M, 1 F

2

2
1

No. of the patient(s)
with skin
manifestations

Najarian, D. J. (20)

USA

Apr 22-2020

Case report

58

1M

1

Gianotti, R. (21)

Italy

Apr 29-2020

Case series

68

1 M, 2 F

3

3

Gianotti, R. (22)

Italy

Apr 30-2020

Case series

–

–

5**

5**

Elderly

–

1

1

56.3

113 M, 121 F

234

234

Sanchez, A. (23)

France

Apr 30-2020

Case report

Galván Casas, C. (24)

Spain

Apr 30-2020

Cross-sectional

Ahouach, B. (25)

France

May 1-2020

Case report

57

1F

1

1

Quintana-Castanedo, L.
(26)

Spain

May 1-2020

Case report

61

1M

1

1
22

Marzano, A. V. (27)

Italy

May 1-2020

Case series

56.4

16 M, 6 F

22

Zengarini, C. (28)

Italy

May 3-2020

Case report

67

1F

1

1

Alramthan, A. (29)

Kuwait

May 5-2020

Case series

31

2F

2

2
1

Henry, D. (30)

France

May 5-2020

Case report

27

1F

1

*Recalcati, S. (31)

Italy

May 6-2020

Case series

72.2

58 M, 49 F

107

3

*Tammaro, A. (32)

Italy

May 6-2020

Case series

–

–

130 + X***

2 + 1***

van Damme, C. (33)

Belgium

May 6-2020

Case report

71

1M

1

1

Avellana Moreno, R. (34)

Spain

May 6-2020

Case report

32

1F

1

1

Amatore, F. (35)

France

May 6-2020

Case report

39

1M

1

1

Suarez-Valle, A. (36)

Spain

May 8-2020

Case series

–

–

3

3

Fernandez-Nieto, D. (37)

Spain

May 8-2020

Case series

45

6 M, 18 F

24

24

Paolino, G. (38)

Italy

May 8-2020

Case report

37

1F

1

1

Diaz-Guimaraens, B. (7)

Spain

May 8-2020

Case report

48

1M

1

1

Bouaziz, J. D. (39)

France

May 8-2020

Case series

–

–

14

14

Locatelli, A. G. (40)

Italy

May 9-2020

Case report

16

1M

1

1

Jimenez-Cauhe, J. (41)

Spain

May 9-2020

Case series

66.7

4F

4

4

Robustelli Test, E. (42)

Italy

May 10-2020

Case report

70

1F

1

1

Gunawan, C. (43)

Indonesia

May 10-2020

Case report

51

1M

1

1

*de Masson, A. (44)

France

May 28-2020

Retrospective private
practices-based study

–

–

25

7
23

Freeman, E. E. (45)

USA

May 30-2020

Case series

41

12 M, 11 F

23

Bosch-Amate, X. (46)

Spain

June 03-2020

Case report

79

1F

1

1

Reymundo, A. (47)

Spain

June 04-2020

Case series

66.6

2 M, 5 F

7

7

Gargiulo, L. (48)

Italy

June 07-2020

Case report

72

1F

1

1

Freeman, E. E. (45)

USA

June 23-2020

Case series

44

78 M, 93 F

165****

165****
34

*Askin, O. (49)

Turkey

June 24-2020

Cross-sectional

NM

NM

122

Ciccarese, G. (50)

Italy

June 24-2020

Case report

19

1F

1

1

*Matar, S. (51)

France

June 26-2020

Case series

55.6

6 M, 2 F

759

8

Ho, W. Y. B. (52)

Singapore

June 26-2020

Case series

59

1 M, 1 F

2

2

Potekaev, N. N. (53)

Russia

July 03-2020

Case series

62.2

7 M, 5 F

12

12
(Continued)
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TABLE 1 | Continued
First author

Country

Published time

Type of study

Mean age

Male/
Female

No. of confirmed
COVID-19
patient(s)

No. of the patient(s)
with skin
manifestations

Le Cleach, L. (54)

France

July 06-2020

Case series

34

3 M, 7 F

10

10

Proietti, I. (55)

Italy

July 22-2020

Case report

6 months

1M

1

1

*Articles that are included for calculating the prevalence of cutaneous manifestations in confirmed COVID-19 patients.
**Total population of cases was 8 but data of 5 patients were available only.
***Tammaro et al. visited 130 patients in a hospital in Rome in which 2 patients had cutaneous manifestations. Also, they visited undetermined (X) patients in Barcelona in which there was
a patient with cutaneous manifestation. Note that for calculating the prevalence number we excluded the latter patient (because of the undetermined number of total case population).
****Total population of confirmed COVID-19 patients was 171 but data of 165 patients were available only.

and vascular (46%) lesions. Disruption of coagulation condition
(increase in PT, INR, and fibrinogen) was reported in patients
with chilblain-like and vascular lesions (Tables 3, 4).
Regarding the drug history and medication regimen used
for COVID-19, data of 389 out of 597 cases were available,
most of which related to maculopapular and urticaria-like
lesions. Fifty-two percentage of all cases and 72% of cases
with chilblain-like lesions underwent symptomatic treatment
with paracetamol, etc., or recovered without any medication.
Chloroquine/hydroxychloroquine was the most common
medication used in patients (45%). Details in Tables 3, 4.
Most patients had mild disease (48%). The majority of patients
with chilblain-like lesions had mild disease (82%) and the
majority of patients with vascular lesions had severe disease
(68%). Also, most of the patients with maculopapular lesions
were moderate (43%) regarding severity (Tables 3, 4).
The overall mortality rate among COVID-19 patients with
cutaneous manifestations was 4.5%. Patients with vascular lesions
had the highest mortality rate (18.2%) and patients with urticarialike lesions had the lowest mortality rate (2.2%).
Details indicating characteristics of the lesions and the
patients are shown in Tables 2–4.

were seen within the epidermis in maculopapular lesions.
Telangiectatic blood vessels were seen within the dermis of
vascular and miscellaneous lesions. Virally-induced cytopathic
alterations were absent according to reports on the miscellaneous
category. Striking vascular and dermal deposits of complement
factors (C5b-9, C3d, C4d) and IgM were present in four vascular
rashes. Some studies performed an RT-PCR test on skin samples
of maculopapular and vesicular lesions and the results were all
negative for SARS-CoV-2. More details can be found in Table 2.
Most lesions required systemic corticosteroids (47%) or had
spontaneous remission (23.5%). Antihistamines were the most
widely used medication especially for urticaria-like lesions (57%).
Systemic corticosteroids were commonly used in vascular lesions
(71%) (Tables 2, 4).

Characteristics of the Confirmed COVID-19
Patients With Skin Manifestations
The overall prevalence of comorbidities among patients with
skin manifestations was 17.9% (Table 4). Hypertension (39%),
diabetes (23%), and dermatologic diseases (20%) were the
most frequent comorbidities, respectively. Utmost cases with
comorbidity were across the patients with maculopapular lesions
(40%). Previous dermatologic illnesses were most common in
patients with vesicular lesions (Table 4). Cardiovascular disease,
hypertension, and obstructive lung diseases were common
comorbidities amongst patients with vascular lesions (Table 4).
Rheumatologic diseases were more frequent in patients with
chilblain-like lesions (30%). Diabetes was seen commonly in
patients with urticaria-like lesions (46%).
Fever (72%), cough (61%), fatigue/myalgia (51%),
and dyspnea (46%) were the most common associated
symptoms amongst the patients. Fever was more frequent
in patients with vascular lesions (84%) and less frequent in
patients with chilblain-like lesions (39.5%). Headache (41%),
dysosmia/hyposmia (27.5%), nasal congestion/coryza (19%), and
irritability/confusion (10%) were mainly seen in patients with
vesicular lesions. Seventeen percentage of patients with chilblainlike lesions, 5% of patients with urticaria-like lesions, and 1%
of patients with maculopapular lesions were asymptomatic.
Bleeding presentations like epistaxis were seen just in patients
with vascular lesions (Tables 3, 4).
Elevated D-dimer was the main laboratory finding in most
of the cases, especially in patients with chilblain-like (100%)

Frontiers in Medicine | www.frontiersin.org

DISCUSSION
After 1 year from the beginning of COVID-19 pandemic, the
world is still facing a crisis. According to the current literature,
more than half of the patients are asymptomatic leading to
uncontrolled transmission of the virus (57–60). Recognizing
COVID-19 related cutaneous manifestations may assist clinicians
in early diagnosis of disease, before the development of
respiratory symptoms, and may also be used to identify
complications requiring treatment. The current study found that
10.5% of the COVID-19 patients reported skin lesions before the
initiation of other symptoms or as their chief complaint. On the
other hand, considering cutaneous manifestations is important
to make the right diagnosis; as Joob et al. reported a COVID19 patient with petechiae misdiagnosed with dengue fever (13).
Our data demonstrated that 34.5% of cutaneous manifestations
occurred at the same time with other symptoms particularly
urticaria-like lesions (47%). It may suggest that urticaria-like
lesions may be a diagnostic sign for COVID-19. The rest of the
skin manifestations appeared later in the course of the disease
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TABLE 2 | Characteristics of the cutaneous lesions in confirmed COVID-19 patients.
Category

Location

Description

Associated cutaneous
symptoms

Rash onset with
other symptoms

Median
duration

Main histologic findings

Locatelli, A. G. (40)

Chilblain-like

Dorsal aspects of the fingers

Asymptomatic
Erythematousoedematous macules and
plaques (Chilblain-like)

After

–

Oedema of the papillary
–
dermis, superficial and deep
lymphocytic infiltrate in a
peri-vascular and strong
peri-eccrine pattern; no signs
of endothelial damage.
consistent with a diagnosis of
chilblains

Alramthan, A. (29)

Chilblain-like

Dorsal aspect of fingers
bilaterally, subungual area of
the thumb

Red-purple papules,
diffused erythema in the
subungual area

–

Chief complaint

–

–

Suarez-Valle, A. (36) Chilblain-like

Toes (3), soles (1) (sparing
palms and mucous
membranes)

Rounded reddish-purple
plaques, measuring
between 0.5 and 1 cm,
sharply defined, with no
retiform borders

–

23 days after

14 days

–
Ischemic necrosis affecting
the epidermis and dermis with
signs of re-epithelialization.
vasculitis or microthrombi
were not found.

de Masson, A. (44)

Chilblain-like

Hands and feet

Acral lesions (chilblains)

–

–

–

Lichenoid dermatitis with a
perivascular and eccrine
mononuclear infiltrate,
vascular microthrombi

Freeman, E. E. (45)

Chilblain-like

Hand (7), foot (20)

Pernio-like acral skin
lesions

Pruritus (8), Pain/Burning
(16)

Before (4), After (11), 14 days
At the same time (3),
No other COVID-19
symptoms (5)

–
Mild vacuolar interface
dermatitis with dense
superficial and deep
lymphocytic inflammation,
consistent with pernio vs.
connective tissue disease. No
thrombi were noted.

Le Cleach, L. (54)

Chilblain-like

Acral area of hand and foot,
dorsum of toes and soles,
lateral part of the foot

Typical chilblains, severe –
form with bullae, erythema
multiform-like lesions,
punctiform purpuric
lesions, diffuse vascular
erythema, and oedema

After/Before

–

Vacuolization or apoptosis of
keratinocytes, superficial and
deep infiltrates mainly of
lymphocytes, perieccrine, and
perivascular reinforcement,
superficial capillary
thrombosis, dermal oedema

Without
treatment,
topical
corticosteroids

Najarian, D. J. (20)

Maculopapular

Legs, thighs, forearms, arms, Morbilliform erythematous Pruritus
shoulders, back, chest, and
macules and patches
abdomen (sparing the face,
hands, feet, and mucosa)

After

–

–

Triamcinolone
0.1%

6

First author

Rash
treatment

–

–
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Category

Location

Description

Associated cutaneous
symptoms

Rash onset with
other symptoms

Median
duration

Main histologic findings

Sanchez, A. (23)

Maculopapular

Trunk, back, thighs, arms

Digitatepapulosquamous
eruption and
erythematous
periumbilical patch
(digitate scaly thin
plaques)

–

7 days after

7 days

Spongiosis, parakeratosis, a No
few rounded spongiotic
vesicles containing
aggregates of lymphocytes
and Langerhans cells.
moderate lymphohistiocytic
infiltration, negative COVID-19
RT-PCR on a fresh skin
biopsy specimen

Hunt, M. (12)

Maculopapular

Trunk and extremities (sparing Diffuse, morbilliform,
Non-pruritic
the face, mucosal or ocular
maculopapular (consistent
involvement)
with a viral exanthem)

At the same time

–

–

–

Ahouach, B. (25)

Maculopapular

Trunk, limbs

Diffuse fixed erythematous Burning
blanching maculopapular
lesions

–

–

Spongiosis, basal cell
vacuolation and mild
perivascular lymphocytic
infiltrate, negative PCR on
whole-skin biopsy specimen
for SARS-CoV-2.

–

AvellanaMoreno, R.
(34)

Maculopapular

Face, neck, thorax, abdomen,
buttocks, extremities including
folds and scalp, respecting
the palmoplantar region and
mucosa

Pruritus
Generalized, pruritic
morbilliform rash
cephalocaudal progress
(petechial and
maculopapular on an
erythematous base), a
scaly reaction occurred on
the fourth day after the
rash started

6 day after

4 days

–

–

Reymundo, A. (47)

Maculopapular

Trunk (7), proximal upper
–
limbs (6), proximal lower limbs
(1)

–

–

–

Mild superficial perivascular
lymphocytic infiltrate

Without
treatment (1),
systemic
corticosteroid
(6)

Maculopapular: trunk, neck
spreading to the cheeks,
upper and lower extremities
(involving the palms)
Urticaria-like: face, upper
extremities spreading to the
trunk and lower extremities
(sparing palms and soles)

Pruritus (1)

After (1), At the
same time (1)

5 days

–

No

Morey-Olive, M. (19) Maculopapular (1),
Urticaria-like (1)

Maculopapular:
erythematous, confluent,
non-pruritic
maculopapular exanthem
Urticaria-like: pruritic
Urticaria-like exanthem

Rash
treatment
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Location

Description

Gianotti, R. (22)

Maculopapular (3),
Vascular (2)

Trunk, limb

Mahé, A. (16)

Miscellaneous

Robustelli Test, E.
(42)

Zengarini, C. (28)

Associated cutaneous
symptoms

Rash onset with
other symptoms

Median
duration

Main histologic findings

Maculopapular:diffusemaculo–
papulovesicular rash and
hemorrhagic dot-like area,
sligthlypapular
erythematous exanthema,
erythematous papular
eruption with crusted and
erosive lesions mimicking
Grover disease
Vascular: diffuse macular
livedoid
hemorrhagic lesions

After (5)

–

–
Maculopapular: classic
dyskeratotic cells, ballooning
multinucleated cells and
sparse necrotic keratinocytes
with lymphocytic satellitosis,
edematous dermis with many
eosinophils, lymphocytic
vasculitis
Vascular: diffuse telangiectatic
small blood vessels in the
dermis, spongiotic dermatitis
with exocytosis along with a
large nest of Langerhans cells
and a dense perivascular
lymphocytic and eosinophilic
infiltration, lymphocytic
vasculitis, Intravascular
microthrombi in the small
dermal vessels.

Both antecubital fossae
extended to the trunk and
axillary folds

Erythematous rash

4 days after

5 days

–

–

Miscellaneous

Face, trunk, upper and lower
limbs (sparing the mucous
membranes, palms, and
soles)

Diffuse pustular eruption: Pruritus
widespread eruption on
an erythematousoedematous base, with
scattered pinhead-sized
pustules and scales,
Targetoid lesions studded
with small pustules in a
symmetric pattern

After

–

Subcorneal pustule with mild
focal acanthosis and
spongiosis, neutrophilic
exocytosis, sparse
keratinocyte necrosis,
perivascular lymphocytic
infiltrate with rare neutrophils
and eosinophils (consistent
with AGEP)

–

Miscellaneous

Neck, trunk, back, proximal
portions of limbs (sparing the
palmoplantar skin, face, and
mucous membranes)

Erythematous confluent
rash, with undefined
margins, bleaching

After

7 days

Slight superficial perivascular –
lymphocytic infiltrate
extremely dilated vessel in the
papillary and mid dermis.

–
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Rash
treatment
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First author

First author

Category

Location

Amatore, F. (35)

Miscellaneous

Gargiulo, L. (48)

Description

Rash onset with
other symptoms

Median
duration

Main histologic findings

Rash
treatment

Upper limbs, chest, neck,
Erythematous and
abdomen, and palms (sparing edematous annular fixed
the face and mucous
plaques
membranes)

Non-pruritic

At the same time

7 days

HCQ

Miscellaneous

Trunk, upper and lower limbs

Pruritus

10 days Before

–

Ciccarese, G. (50)

Miscellaneous

Lower limbs, Inner surface of
the lips, platelet, gingiva

Asymptomatic

5 days after

12 days

Predominantly superficial
perivascular infiltrate of
lymphocytes without
eosinophils, papillary dermal
edema, subtle epidermal
spongiosis, lichenoid, and
vacuolar interface dermatitis
with occasional dyskeratotic
keratinocytes in the basal
layer. No virally-induced
cytopathic alterations or
intranuclear inclusions were
present. Direct
immunofluorescence was
negative.
Mixed perivascular and
interstitial infiltrate including
lymphocytes, granulocytes,
histiocytes, plasma cells, and
mast cells.
–

Recalcati, S. (6)

Miscellaneous (14),
Urticaria-like (3),
Vesiclular (1)

Trunk

Low or absent pruritus

At the same time (8), Few days
After (10)

–

Gianotti, R. (21)

Maculopapular (3)

Arms, trunk, lower limbs

Pruritus (1)

After (2), Before (1)

No (3)
Perivascular dermatitis with
slight lymphocytic exocytosis
in a vasculitic pattern.
vascular thrombosis, Swollen
thrombosed vessels with
neutrophils, eosinophils and
nuclear debris, extravasated
red blood cells, focal
acantholyticsuprabasal clefts,
dyskeratotic and ballooning
herpes-like keratinocytes,
swollen vessels in the dermis
with dense lymphocyte
infiltration, mixed with rare
eosinophils. a nest of
Langerhans within the
epidermis.

9

Associated cutaneous
symptoms

Erythema multiforme-like
(erythematous and slightly
edematous patches,
along with some isolated
typical target lesions)
Cutaneous lesions:
erythematous macules,
papules, and petechiae
Oropharyngeal lesions:
erosions, ulcerations,
blood crusts, petechiae
Erythematous rash (14),
widespread urticaria (3),
chickenpox-like vesicles
(1)
Widespread erythematous
macules, erythematous
crusted macules, and
papules

5, 8, 10 days
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corticosteroid

–

–
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First author

Category

Location

Description

Associated cutaneous
symptoms

Rash onset with
other symptoms

Median
duration

Main histologic findings

Jimenez-Cauhe, J.
(41)

Miscellaneous (4)

Upper trunk, coalescing in the
back, and then spread to the
face and limbs within 1 week
(without the involvement of
palms and soles), platal
macules and petechiae (3)

Erythematous papules
that progressively turned
to erythemato-violaceous
patches with a dusky
center, and a
pseudo-vesicle in the
middle, typical target
lesions (2).

–

19.5 days after

17.5 days

Normal basket-weave stratum Systemic
corneum, mild to moderate
corticosteroids
spongiosis in the epidermis,
dilated vessels filled with
neutrophils, extravasation of
red blood cells, lymphocytic
perivascular and interstitial
infiltrate, Basal vacuolar
changes with interface
dermatitis, lymphocytic
exocytosis

Galván Casas, C.
(24)

Chilblain-like (29),
Vesicular (17),
Urticaria-like (49),
Maculopapular
(122), Vascular (17)

Chilblain-like: acral areas of
hands and feet. usually
asymmetrical
Vesicular: trunk, limbs
Urticaria-like: mostly trunk, a
few cases were palmar
Maculopapular: extremities,
mostly dorsum of the hands
Livedo/necrosis: trunk,
acral area

Pseudo-chilblain (29),
–
Vesicular (17), Urticarial
(49), Maculopapules (122),
Livedo/necrosis (17)

Before (9), At the
same time (147),
After (77)

–
Chilblain-like:
12.7 days
Vesicular: 10.4
days
Urticaria-like:
6.8 days
Maculopapular:
8.6 days

–

Fiehn, C. (15)

Urticaria-like

Both heels

Confluent
erythematous-yellowish
papules and plaques

Pruritus

13 days After

–

–

Urticaria

Pruritus

–

Rash
treatment

Urticaria-like

Face

5 days After

1

Urticaria-like

Thighs, arms, and forearms
Urticarial rash consisting Mild pruritus
(sparing the palms and soles) of confluent, edematous,
and erythematous papules

Chief complaint

7 days

–

Antihistamine

Henry, D. (30)

Urticaria-like

Face, acral area, palm

Disseminated
Pruritus
erythematous plaques
(Urticaria), papules in palm

Before

–

–

Antihistamine

van Damme, C. (33) Urticaria-like

–

Extensive acute urticarial
rash

At the same time

–

–

Bilastine

Paolino, G. (38)

Urticaria-like

Trunk, neck, face, lower limbs An urticaria-like lesion with Non-pruritic
craniocaudal development

3 days after

8 days

–

–

Proietti, I. (55)

Urticaria-like

Trunk, limbs

Giant urticaria with
multiple lesions

–

14 days after
RT-PCR test (no
associated
symptoms)

–

–

Oral
betamethasone

Zulfiqar, A. A. (17)

Vascular

Lower extremity

Purpura

–

5 days after

13 days

–

IVIG,
Prednisolone,
Platelet
transfusion

Joob, B. (13)

Vascular

–

Petechiae

–

–

–

–

No

–

Loratadine

(Continued)
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First author

Category

Diaz-Guimaraens, B. Vascular
(7)

11

Location

Description

Associated cutaneous
symptoms

Rash onset with
other symptoms

Median
duration

Main histologic findings

Rash
treatment

Symmetric periflexural
distribution: buttocks,
popliteal fossae, proximal
anterior thighs, and lower
abdomen (sparing the crural
folds and mucosa)

Confluent erythematous
macules, papules, and
petechiae

Slightly pruritic

3 days after

5 days

0.05%
Betamethasone
dipropionate
cream,
Loratadine

–

4 days after

–

–

–

Perivascular lymphocytic
infiltrate, red cell
extravasation, and focal
papillary edema, along with
focal parakeratosis and
isolated dyskeratotic cells. No
features of thrombotic
vasculopathy were present
Thrombogenic vasculopathy,
extensive necrosis of the
epidermis and adnexal
structures, interstitial and
perivascular neutrophilia with
prominent leukocytoclasia,
superficial vascular ectasia,
perivascular lymphocytic
infiltration, absence of clear
vasculitis, Significant vascular
deposits of C5b-9, C3d, and
C4d (in all cases)
–

–

12 days to
death

–

–

–

–

–

A few days after

–

Multiple thrombi occluding
most small-sized vessels of
the superficial and
mid-dermis, deposition of
IgM, C3, C9, and fibrinogen
within superficial-to-deep
dermal blood vessel walls.
–

Vascular

Buttocks, palms and soles,
chest, legs, and arms

Purpuric reticulated
eruptions with
surrounding inflammation
(Livedoracemosa)

Recalcati, S. (6)

Vascular

Acral area, foot

Zhang, Y (14)

Vascular

Finger/toe

Bosch-Amate, X.
(46)

Vascular

Both legs

Acrocyanosis (2), foot
–
thrombosis (1)
–
Acro-ischemia including
cyanosis, bulla, and dry
gangrene
Retiform
Pain
purpuric-violaceous
patches of 15 cm with
some hemorrhagic blisters
and crusts suggestive of
retiform purpura

Bouaziz, J. D. (39)

Vesicular (2),
Urticaria-like (1),
Chilblain-like (2),
Vascular (3),
Miscellaneous (6)

Inflammatory lesions were –
reported in 7 patients:
exanthema (4),
chickenpox like vesicles
(2), cold urticaria (1),
Vascular lesions were
reported in 7 patients:
violaceous macules with
“porcelain-like”
appearance (1), livedo (1),
nonnecroticpurpura (1),
necrotic purpura (1),
chilblain appearance with
Raynaud’s phenomenon
(1), chilblain (1), eruptive
cherry angioma (1).

–

–

–

(Continued)
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Location

Description

Rash onset with
other symptoms

Median
duration

Main histologic findings

Rash
treatment

Marzano, A. V. (27)

Vesicular (22)

Trunk (22), limbs (4)

Scattered (16), diffuse (6), Mild pruritus (9)
Predominance of vesicles
(12), varicella-like
exanthem

3 days after

8 days

Basket-wave hyperkeratosis,
absence of inflammatory
infiltrate, atrophic epidermis,
vacuolar alteration with
disorganized keratinocytes
lacking orderly maturation,
enlarged and multinucleate
keratinocytes with
dyskeratotic (apoptotic) cells.

–

Fernandez-Nieto, D. Vesicular (24)
(37)

Head (4), anterior trunk (21),
posterior trunk (14), arms (8),
legs (10), palms-soles (2)

18 disseminated pattern Pruritus (20),
Asymptomatic (4)
(small papules, vesicles,
and pustules with varying
sizes of up to 7–8 mm
diameter, different stages
of the lesions appeared
simultaneously), 6
localized pattern
(monomorphic lesions, of
up to 3–4 mm diameter, at
the same stage of
evolution, mostly trunk
involvement)

Before (2), At the
same time (3), After
(19)

10 days

–
Intraepidermal vesicles with
mild acantolisis and ballooned
keratinocytes consistent with
a viral infection, negative
SARS-CoV-2 RT-PCR on fluid
content of the vesicles

Tammaro, A. (32)

Trunk, back

Isolated herpetiform
lesions: lesions were
characterized by vesicles
surrounded by
erythematous halos. In
one of the patients, the
vesicles had started to
form crusts, numerous
vesicular isolated lesions
on her back.

After

–

–

12

First author

Vesicular

Associated cutaneous
symptoms

Mild pruritus

–
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(Continued)

Potekaev, N. N. (53) Chilblain-like (1),
Vesicular (2),
Urticaria-like (1),
Maculopapular (4),
Vascular (4)

Lower limb (6), upper limb (5),
trunk (4), first MTP joints (1),
ankles and dorsal surfaces of
the feet and toes (1)

13

Freeman, E. E. (56)

Chilblain-like (31),
Vesicular (18),
Urticaria-like (27),
Maculopapular (78),
Vascular (11)

Matar, S. (51)

Maculopapular,
Vesicular,
Miscellaneous

Category

Associated cutaneous
symptoms

Rash onset with
other symptoms

Median
duration

Main histologic findings

Rash
treatment

Vascular: papulonecrotic Pain (1), Pruritus (1)
rash with hemorrhagic
crusts, polymorphic
cutaneous vasculitis,
dense petechial and
ecchymotic rash
Chilblain-like: hyperemic
pernio-like lesions
Maculopapular: spotted
elements of bright pink
color, papulosquamous
rash (pytriasis rosea-like,
absence of the herald
patch), disseminated
pink-red maculopapular
rash resembling that of
measles, large bright red
foci
Vesicular: papulovesicular
eruptions with
surface erosions

Before (1), At the
same time (1), After
(5)

–

–

Without
treatment (1),
Systemic
corticosteroid
(3)

Hand (38), foot (51), face (32),
head (11), neck (26), chest
(49), abdomen (63), back (62),
arm (66), genitals (7),
leg/buttocks (72), entire body
(9)

Pruritus (97), Burning/pain
Maculopapular:
morbilliform rash, macular (55)
erythema,
papulosquamous
Vascular: retiform purpura

Before (17), After
(107), At the same
time (29), Chief
complaint (10)

–

–
Vascular: thrombotic
vasculopathy, leukocytoclastic
vasculitis
Maculopapular: spongiosis
and dermal inflammation
Chilblain-like: vacuolar
interface dermatitis,
subepidermal edema, and
superficial and deep
lymphocytic inflammation
Miscellaneous (actually
distributed petechial, macular,
and urticarial eruption):
numerous dyskeratotic
keratinocytes, sparse
perivascular lymphohistiocytic
inflammation, and rare
dermal eosinophils.

-

Disseminated
maculopapular
exanthema, digitate
papulosquamous rash,
herpes recurrence,
papulovesicular rash,
Grover’s disease

13 days after

–

–

–

–

(Continued)
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7 days, 10 days Miscellaneous: spongiotic and Topical
interface dermatitis, superficial corticosteroids
perivascular infiltrate of
(2)
predominantly lymphocytes,
focal erythrocyte extravasation
without vasculitis. There were
no viral cytopathic or
herpetic changes.

Skin Manifestations in COVID-19 Patients

Miscellaneous:
–
erythematous, blanchable,
non-follicular papules,
non-follicular pinpoint
pustules within the
intertriginous areas
Vascular: purpuric plaques

Miscellaneous: 12
days after
Vascular: 15
days after

and mainly after the initiation of systemic symptoms (55%)
in our review. Galván Casas et al. suggested the chilblain-like
and vesicular lesions as epidemiological markers for the disease
(24). However, in our study, vesicular lesions (74%) were the
most important cutaneous manifestations usually appearing after
systemic symptoms of the disease.
Most of the patients with skin manifestations were middleaged females, while, patients with chilblain-like lesions were
younger (mean age: 40.7 years) and patients with vascular lesions
were older individuals (mean age: 72.3 years). These findings are
along with other studies about the chilblain-like lesions (6, 19, 24,
40). Maculopapular lesions were the most common dermatologic
presentation of COVID-19 patients that commonly appeared at
extremities. It occurred most often in middle-aged patients and
was associated with moderate COVID-19 severity.
The overall mortality rate between the COVID-19 patients
with skin presentations was 4.5%, with the point that there was
the lowest mortality rate among the patients with urticaria-like
lesions (2.2%) and contradictory, there was the highest mortality
rate among the patients with vascular lesions (18.2%). Previous
studies showed a pooled mortality rate of 3.2–6% in patients
with COVID-19 (61, 62). Thus, the mortality rate of COVID-19
patients with skin manifestations is proportionate to the overall
mortality rate of the disease.
Regardless of the type of skin lesions, 80% of COVID-19
patients with cutaneous manifestations experienced a mild and
moderate, and 20% a severe COVID-19 disease. A previous study
from the Chinese Center for Disease Control and Prevention
reported that 81% of COVID-19 patients had a mild, 14% a
severe, and 5% a critical disease (63). We don’t have any specific
data on patients without skin manifestations but comparing the
COVID-19 severity in patients with skin manifestations and
COVID-19 patients, regardless of their symptoms, demonstrates
no obvious difference. Future cohort studies are required to
compare the disease severity and outcome of COVID-19 patients
with and without skin manifestations.
There is a wide range of cutaneous manifestations related
to COVID-19 that in terms of age, associated symptoms,
comorbidity, medication, severity, and mortality, chilblainlike lesions, and vascular lesions are the ends of this
spectrum. Chilblain-like, urticaria-like, vesicular, maculopapular,
miscellaneous, and vascular lesions are associated with an
increase in COVID-19 severity and worsening the prognosis,
respectively. Vascular lesions were more prevalent in males (61%)
compared to females (39%). Considering the more severe disease
and higher mortality rate in patients with vascular lesions, we
can conclude that COVID-19 is more severe in males compared
to females. This finding is compatible with our recent article, in
which we assessed the sex-specific risk of mortality in COVID-19
patients (62).
Up to date, there is conflicting information about the
potential possibility of transmitting the virus through the skin
(37, 40, 64). Further investigations are required to identify the
pathophysiology of SARS-COV-2 and to determine whether
patients with long-lasting skin lesions (e.g., chilblain-like lesions)
are capable of infecting other individuals through skin contact
or not.

Miscellaneous (1),
Vascular (1)
Ho, W. Y. B. (52)

Miscellaneous: Trunk,
proximal thighs, intertriginous
areas including bilateral axillae
and groin
Vascular: abdomen, back

Category
First author
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Description

Associated cutaneous
symptoms

Rash onset with
other symptoms

Median
duration

Main histologic findings

Rash
treatment
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TABLE 3 | Characteristics of the confirmed COVID-19 patients with skin manifestations.
First author

Comorbidity

Associated symptoms

Drug history

Laboratory findings

Severity/outcome

Locatelli, A. G. (40)

–

Dysgeusia, mild diarrhea

–

–

Non-severe

Alramthan, A. (29)

–

Asymptomatic

–

–

–

Suarez-Valle A. (36)

–

–

–

D-dimer↑, fibrinogen↑

Non-severe

de Masson, A. (44)

–

–

–

–

–

Freeman EE. (45)

HTN (2), obstructive lung
disease (2), reumatologic
disease (2)

Fever (9), cough (9), dyspnea
(6), sore throat (5), headache
(7), malaise (4), asymptomatic
(5)

–

–

Outpatient care only (18), Hospitalized
(5), Death (2)

Le Cleach L. (54)

Raynaud syndrome (2)

Fever (2), cough (2), dyspnea
(3), asthenia (5), myalgia (3),
headache (7), odynophagia
(3), anosmia/ageusia (5),
asymptomatic (3)

–

–

Outpatient (10)

Najarian, D. J. (20)

–

Cough, pain in leg and hands

Azithromycin, Benzonatate

–

Non-severe

Sanchez, A. (23)

T2D, HTN, peripheral
artery disease, chronic
renal failure

Fatigue, fever, dyspnea, acute
respiratory distress

Cefpodoxime

EBV PCR positive (reactivation of
EBV)

Severe/ Death

15

–

Fever

–

Lymphopenia, CRP↑

Severe

–

Fever, dry cough

Paracetamol

–

–

Avellana Moreno, R. (34)

–

Fever, myalgia, asthenia,
cough, diarrhea

Paracetamol

–

–

Reymundo A. (47)

–

–

–

–

–

Morey-Olive, M. (19)

Cholestatic liver disease
(1)

Low-grade fever

Oral symptomatic treatment

Worsening of the markers for
cholestasis

–

Gianotti, R. (22)

–

Fever, sore throat, cough

Levofloxacin (3), HCQ (3)

–

Mild (2), Moderate (2), Severe (1)

Mahé, A. (16)

T2D

Fever, asthenia, cough

Paracetamol

–

Non-severe/Survived

Robustelli Test, E. (42)

–

–

Lopinavir/ritonavir, HCQ (3 weeks
before)

–

–

Zengarini, C. (28)

Moderate obesity, a
history of alcoholism, and
various chronic
morbidities

Progressive dyspnoea, fever

HCQ, Omeprazole,
Piperacillin/Tazobactam, Remdesevir,
Potassium canreonate, and
Enoxaparine.

–

Severe

Amatore, F. (35)

–

Fever

HCQ

Blood count: NL, electrolytes: NL,
CRP: NL, anti-DNA antibodies: NL

Gargiulo L. (48)

–

Fever

Paracetamol, Darunavir/cobicistat,
HCQ

–

Severe, Death

Ciccarese G. (50)

–

Fever, sore throat, fatigue,
hyposmia

Cefixime (3 days earlier discontinued),
IVIG, Methylprednisolone

Leukocytosis, Lymphocytosis, severe
Thrombocytopenia, LFT↑, LDH↑

–

Recalcati S. (6)

–

–

–

–

–
(Continued)
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TABLE 3 | Continued
Associated symptoms

Drug history

Laboratory findings

Severity/outcome

Gianotti, R. (21)

–

Fever (2), cough (2), headache
(1), arthralgias (1)

Lopinavir/Ritonavir (1), Heparin (1),
Levofloxacin (2), Ceftriaxone (1),
Azithromycin (1), HCQ (1)

CRP↑, fibrinogen↑, ALT↑, AST↑

Mild (1), Severe (2)

Jimenez-Cauhe J. (41)

–

–

Lopinavir/Ritonavir, HCQ,
Azithromycin, Corticosteroids,
Ceftriaxone

Laboratory tests at the time of skin
lesions showed worsening of one or
more parameters compared to those
at the time of discharge (CRP↑,
D-dimer↑, lymphocyte count↓)

–

Galván Casas C. (24)

–

Cough, dyspnea, fever,
asthenia, headache,
nausea/vomiting/diarrhea,
anosmia, ageusia, pneumonia

–

–

Pseudo-chilblain: less severe
Vesicular lesions: intermedium
severity
Urticarial and maculopapular lesions:
more severe COVID-19 disease
Livedoid/necrotic lesions: the most
severe disease

Estébanez, A. (5)

–

Dry cough, nasal congestion,
fatigue, myalgias, arthralgias,
diarrhea, ageusia, anosmia

Paracetamol

–

–

Gunawan, C. (43)

HTN, diabetes,
dyslipidemia,
hyperuricemia

Fever, cough, dyspnea,
diarrhea

Azithromycin, HCQ,
Cefoperazone-sulbactam,
Omeprazole, medicines for his
comorbidities

–

Non-severe

Quintana-Castanedo, L.
(26)

–

4-day history of progressive
cutaneous rash

–

–

–

Henry, D. (30)

–

Odynophagia, diffuse
arthralgia, chills, chest pain,
fever

Paracetamol

Moderate lymphopenia, CRP↑

Non-severe

van Damme, C. (33)

Obesity, T1D,
hypercholesterolemia,
HTN, obstructive sleep
apnea-hypopnea
syndrome, stroke 18
months ago without
further sequelae, kidney
failure on dialysis

General weakness, fever

–

Mild lymphopenia, CRP↑, LFT (GOT,
GPT, LDH, GGT)↑

Severe/Death

Paolino, G. (38)

–

7th postpartum day, fever, dry
cough, myalgia, arthralgia

Paracetamol

–

–

Proietti I. (55)

–

Asymptomatic

–

Normal

–

Zulfiqar, A. A. (17)

HTN, autoimmune
hypothyroidism

Fatigue, fever, dry cough,
abdominal discomfort,
epistaxis

IV Amoxicillin–Clavulanic acid, LMWH

CRP↑, LFT showed cholestasis,
progressive thrombocytopenia,
fibrinogen↑, TPO↑

–

Joob, B. (13)

–

Fever, pneumonia, bleeding
presentation (firstly missed
diagnosed to be dengue)

–

–

–
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TABLE 3 | Continued
First author

Comorbidity

Associated symptoms

Drug history

Laboratory findings

Severity/outcome

Diaz-Guimaraens, B. (7)

HTN

Fever, pleuritic chest pain,
shortness of breath

Telmizartan, HCQ, LR, Azithromycin

Lymphopenia, CRP↑, D-dimer↑

Non-severe

Magro, C. (18)

Obesity-associated sleep
apnea, anabolic steroid
use

Fever, cough, dyspnea,
diarrhea, chest pain, myalgia

HCQ, Azithromycin, Remdesivir,
prophylactic Enoxaparin

D-dimer↑, INR↑, CH50↑, C3↑, C4↑,
Thrombocytopenia

Severe

Recalcati S. (6)

–

–

–

–

–

Zhang, Y (14)

HTN, DM, CAD

Fever, cough, dyspnea,
diarrhea

LMWH

D-dimer↑, fibrinogen↑, FDP↑, PT↑

Severe/Death (5)

Bosch-Amate X. (46)

–

Fever, asthenia, cough,
shortness of breath

HCQ, Azithromycin, LR, LMWH,
Fondaparinux

Leukopenia, CRP↑, D-dimer↑

Hospitalized, Survival

–

–

–

–

–

Fever (21), cough (16),
headache (11), weakness
(11), coryza (10), dyspnea (9),
hyposmia (4), hypogeusia (4),
pharyngodynia (1), diarrhea
(1), myalgia (1)

–

–

Mild (10), Moderate (2), Severe (10)/
Death (3)

Fernandez-Nieto, D. (37)

Atopic dermatitis (5),
chronic urticaria (2)

–

7 patients: Lopinavir/Ritonavir (5),
HCQ (6), Azithromycin (2)

–

Mild (14), Moderate (9), Severe (1)

Tammaro A. (32)

–

–

–

–

–

Potekaev NN. (53)

–

Fever (2), cough (1), weakness
(1), shortness of breath (1)

HCQ (1)

–

Severe (2)

Freeman EE. (56)

HTN (32), diabetes (19),
obstructive lung disease
(14), Non-obstructive lung
disease (9), cardiovascular
disease (5), kidney
disease (5), reumatologic
disease (5), hidradenitis
suppurativa (2), contact
dermatitis (5), alopecia
areata (4), melanoma (3)

Fever (103), cough (92),
dyspnea (64), sore throat (62),
headache (54), diarrhea,
vomiting or nausea (51),
malaise (45), myalgia (35),
irratibility/confusion (27), chest
pain (27), abdominal pain (23),
anosmia (18), dysgeusia (12),
arthralgia (16), rhinorrhea (14),
asymptomatic (11)

Bevacizumab (12), Remdesivir (9),
Lopinavir/Ritonavir (2), supportive
care only (96), anti-malarials (41),
antibiotics (40), serpin inhibitors (6),
IL-6 inhibitors (4), JAK inhibitors (2)

–

Out-patient (95), Hospitalized (17),
Non-invasive ventilation or high flow
oxygen, ventilator and/or ECMO
required (24), Death (8)

Matar S. (51)

–

–

–

–

–

Ho WYB. (52)

–

–

Lopinavir/Ritonavir

–

–
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TABLE 4 | Summary of characteristics of the patients based on the type of lesions.
Characteristics

Chilblain-like
lesions

Vesicular
lesions

Urticaria-like
lesions

Maculopapular
lesions

Vascular
lesions

Miscellaneous

Total

110 (18.4)

89 (15)

89 (15)

223 (37.3)

55 (9.2)

31 (5.2)

597

97

83

85

219

46

11

541

Male, n (%)

43 (44)

42 (51)

28 (33)

107 (49)

28 (61)

2 (18)

250 (46)

Female, n (%)

54 (56)

41 (49)

57 (67)

112 (51)

18 (39)

9 (82)

291 (54)

40.7

56.1

46.3

56.4

72.3

48

53.3

0

85

91

143

21

23

363

N (%)
Sex, N*

Age, mean
Rash location
Trunk, n
Upper Limb, n

24

44

29

194

8

9

308

Lower Limb, n

53

42

30

188

18

10

341

Head/Neck, n

0

12

20

42

0

7

81

Palms/Soles, n

1

2

2

1

1

1

8

Acral area (Finger, Toe), n

69

0

1

0

18

0

88

0

2

1

4

4

2

13

Associated cutaneous symptoms,
n (%)

The mucous membrane, n

74 (67)

62 (70)

80 (90)

159 (71)

18 (33)

4 (13)

397 (66)

Pruritus, n (%)

28 (38)

55 (89)

22 (27.5)

126 (79)

4 (22)

3 (75)

238 (60)

Burning, n (%)

40 (54)

11 (18)

7 (9)

23 (14)

2 (11)

0 (0)

83 (21)

47 (63.5)

9 (14.5)

6 (7.5)

19 (27)

3 (17)

0 (0)

84 (21)

91

86

85

222

41

17

542

Before, n (%)

10 (11)

5 (6)

5 (6)

14 (6)

1 (2)

1 (6)

36 (7)

Chief complaint, n (%)

13 (14)

0 (0)

3 (3.5)

3 (1)

0 (0)

0 (0)

19 (3.5)

Pain, n (%)
The onset of the lesions in relation
toother symptoms, N

At the same time, n (%)

21 (23)

17 (20)

40 (47)

92 (41)

16 (39)

1 (6)

187 (34.5)

After, n (%)

45 (49)

64 (74)

37 (43.5)

113 (51)

24 (58.5)

15 (88)

298 (55)

14

9

5.25

7.4

9.5

9.3

9

Median duration of skin lesions,
day

0

0

7

15

5

7

34

Without treatment, n (%)

Rash treatment, N**

0 (0)

0 (0)

0 (0)

7 (47)

1 (20)

0 (0)

8 (23.5)

Antihistamines, n (%)

0 (0)

0 (0)

4 (57)

0 (0)

1 (20)

0 (0)

5 (15)

Topical corticosteroids, n (%)

0 (0)

0 (0)

1 (14)

1 (7)

2 (40)

1 (14)

5 (15)

Systemic corticosteroids, n (%)

0 (0)

0 (0)

2 (28.5)

7 (47)

2 (40)

5 (71)

16 (47)

Hydroxychloroquine, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (14)

1 (3)

Comrbidity, N*** (%)

20 (19)

14 (13)

13 (12)

43 (40)

15 (14)

2 (2)

107 (100)

Hypertension

6 (30)

3 (21)

5 (38)

16 (37)

12 (80)

0 (0)

42 (39)

Diabetes

0 (0)

2 (14)

6 (46)

10(23)

6 (40)

1 (50)

25 (23)

Previous dermatologic illness****

2 (10)

8 (57)

1 (8)

10 (23)

0 (0)

0 (0)

21(20)

Obstructive lung disease

2 (10)

1 (7)

1 (8)

6 (14)

6 (40)

0 (0)

16 (15)

Non-obstructive lung disease

1 (5)

1 (7)

3 (23)

4 (9)

0 (0)

0 (0)

9 (8)

Rheumatologic disease

6 (30)

1 (7)

0 (0)

1 (2)

1 (7)

0 (0)

9 (8)

Chronic kidney disease

0 (0)

0 (0)

1 (8)

6 (14)

0 (0)

0 (0)

7 (6.5)

Cardiovascular disease

1 (5)

0 (0)

0 (0)

3 (7)

2 (13)

0 (0)

6 (6)

Obesity

0 (0)

0 (0)

1 (8)

0 (0)

1 (7)

1 (50)

3 (3)

Obstructive sleep apnea

0 (0)

0 (0)

1 (8)

0 (0)

1 (7)

0 (0)

2 (2)

Dyslipidemia

0 (0)

0 (0)

2 (15)

0 (0)

0 (0)

0 (0)

2 (2)

Liver disease

0 (0)

0 (0)

0 (0)

1 (2)

0 (0)

0 (0)

1 (1)

Peripheral artery disease

0 (0)

0 (0)

0 (0)

1 (2)

0 (0)

0 (0)

1 (1)

Autoimmune hypothyroidism

0 (0)

0 (0)

0 (0)

0 (0)

1 (7)

0 (0)

1 (1)

Hyperuricemia

0 (0)

0 (0)

1 (8)

0 (0)

0 (0)

0 (0)

1 (1)

Stroke

0 (0)

0 (0)

1 (8)

0 (0)

0 (0)

0 (0)

1 (1)

Alcoholism

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (50)

1 (1)
(Continued)
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TABLE 4 | Continued
Characteristics

Associated symptoms, N*****

Chilblain-like
lesions

Vesicular
lesions

Urticaria-like
lesions

Maculopapular
lesions

Vascular
lesions

Miscellaneous

Total

96

58

83

210

43

6

496

38 (39.5)

48 (83)

63 (76)

169 (80)

36 (84)

5 (83)

359 (72)

Cough, n (%)

35 (36)

40 (69)

51 (61)

146 (69.5)

31 (72)

1 (17)

304 (61)

Fatigue/Myalgia, n (%)

42 (44)

33 (57)

46 (55)

113 (54)

15 (35)

2 (33)

251 (51)

Dyspnea, n (%)

27 (28)

22 (38)

33 (40)

120 (57)

27 (63)

1 (17)

230 (46)

Headache, n (%)

32 (33)

24 (41)

26 (31)

64 (30)

7 (16)

0 (0)

153 (31)

Nausea/Vomiting/Diarrhea/Abdominal
discomfort, n (%)

17 (18)

14 (24)

31 (37)

77 (37)

14 (32.5)

0 (0)

153 (31)

Fever, n (%)

Dysosmia/Dysgeusia, n (%)

21 (22)

16 (27.5)

22 (26.5)

39 (18.5)

3 (7)

1 (17)

102 (20.5)

Sore throat, n (%)

13 (13.5)

10 (17)

11 (13)

33 (16)

3 (7)

1 (17)

71 (14)

Chest pain, n (%)

2 (2)

4 (7)

8 (10)

12 (6)

2 (5)

0 (0)

28 (6)

Nasal congestion/Coryza, n (%)

5 (5)

11 (19)

5 (6)

4 (2)

0 (0)

0 (0)

25 (5)

Irritability/Confusion

3 (3)

6 (10)

5 (6)

13 (6)

0 (0)

0 (0)

27 (5)

Arthralgia, n (%)

1 (1)

3 (5)

6 (7)

10 (5)

1 (2)

0 (0)

21 (4)

Bleeding presentation, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

2 (5)

0 (0)

2 (0.4)

Chills, n (%)

0 (0)

0 (0)

1 (1)

0 (0)

0 (0)

0 (0)

1 (0.2)

Odynophagia, n (%)

3 (3)

0 (0)

1 (1)

0 (0)

0 (0)

0 (0)

4 (0.8)

Asymptomatic, n (%)

16 (17)

0 (0)

4 (5)

3 (1)

0 (0)

0 (0)

23 (5)

3

0

2

10

26

12

53

D-dimer increase, n (%)

3 (100)

0 (0)

0 (0)

0 (0)

12 (46)

3 (25)

18 (34)
10 (19)

Laboratory Findings, N******
Fibrinogen increase, n (%)

2 (67)

0 (0)

0 (0)

0 (0)

8 (31)

0 (0)

FDP increase, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

7 (27)

0 (0)

7 (13)

PT/INR increase, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

6 (23)

0 (0)

6 (11)
9 (17)

CRP increase, n (%)

0 (0)

0 (0)

1 (50)

3 (30)

3 (11.5)

2 (17)

Leukopenia, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

1 (4)

0 (0)

1 (2)

Leukocytosis, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (8)

1 (2)
6 (11)

Lymphopenia, n (%)

0 (0)

0 (0)

1 (50)

2 (20)

1 (4)

2 (17)

Thrombocytopenia, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

2 (8)

1 (8)

3 (6)

LFT increase, n (%)

0 (0)

0 (0)

0 (0)

3 (30)

1 (4)

1 (8)

5 (9)

CH50, C3, C4increase, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

1 (4)

0 (0)

1 (2)

COVID-19 treatment, n (%)

46

40

69

185

39

10

389

Paracetamol, symptomatic or without
treatment, n (%)

33 (72)

21 (52.5)

39 (56.5)

103 (56)

5 (13)

3 (30)

204 (52)

Chloroquine/Hydroxychloroquine, n
(%)

9 (19.5)

16 (40)

27 (39)

90 (49)

26 (67)

8 (80)

176 (45)

Lopinavir/Ritonavir, n (%)

90 (23)

3 (6.5)

7 (17.5)

14 (20)

52 (28)

9 (23)

5 (50)

Azithromycin, n (%)

2 (4)

7 (17.5)

13 (20)

38 (20.5)

4 (10)

4 (40)

68 (17)

Other antibiotics*******, n (%)

4 (9)

4 (10)

7 (10)

22 (12)

12 (31)

4 (40)

53 (14)
37 (9.5)

Systemic corticosteroids, n (%)

1 (2)

3 (7.5)

5 (7)

19 (10)

5 (13)

4 (40)

NSAIDs, n (%)

4 (9)

1 (2.5)

3 (4)

10 (5)

17 (43.5)

0 (0)

35 (9)

Tocilizumab (IL-6 inhibitors), n (%)

2 (4)

2 (5)

4 (6)

9 (5)

5 (13)

0 (0)

22 (6)

Bevacizumab, n (%)

0 (0)

2 (5)

4 (6)

6 (3)

0 (0)

0 (0)

12 (3)

LMWH, n (%)

0 (0)

0 (0)

0 (0)

1 (0.5)

9 (23)

1 (10)

11 (3)

Remdesivir, n (%)

1 (2)

1 (2.5)

2 (3)

4 (2)

2 (5)

1 (10)

11 (3)

Serpin inhibitors, n (%)

1 (2)

1 (2.5)

1 (1)

3 (2)

0 (0)

0 (0)

6 (1.5)

Omeprazole, n (%)

0 (0)

0 (0)

1 (1)

0 (0)

0 (0)

1 (10)

2 (0.5)

JAK inhibitors, n (%)

2 (4)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

2 (0.5)

Telmizartan, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

1 (2.5)

0 (0)

1 (0.2)
1 (0.2)

Fondaparinux, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

1 (2.5)

0 (0)

Darunavir/cobicistat, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (10)

1 (0.2)

IVIG, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (10)

1 (0.2)
(Continued)
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TABLE 4 | Continued
Characteristics

COVID-19 severity********, N

Chilblain-like
lesions

Vesicular
lesions

Urticaria-like
lesions

Maculopapular
lesions

Vascular
lesions

Miscellaneous

Total

96

63

79

201

44

4

487

Mild, n (%)

79 (82)

32 (51)

40 (51)

79 (39)

2 (5)

2 (50)

234 (48)

Moderate, n (%)

13 (14)

18 (29)

28 (35)

86 (43)

12 (27)

0 (0)

157 (32)

4 (4)

13 (21)

11 (14)

36 (18)

30 (68)

2 (50)

96 (20)

4 (3.6)

3 (3.4)

2 (2.2)

7 (3.1)

10 (18.2)

1 (3.2)

27 (4.5)

Severe, n (%)
Death, n (%)*********

FDP, fibrinogen degradation product; PT, prothrombin time; LFT, liver function test.
*Number of patients that their gender is reported in the articles.
**Number of patients that articles mentioned their specific treatment for the lesions.
***Number of patients reported having comorbidities in the articles.
****E.g., atopic dermatitis, chronic urticaria, melanoma, alopecia areata, hidradenitis suppurativa.
*****Number of patients that articles mentioned their associated symptoms.
******Number of patients that their laboratory findings are reported in the articles.
*******Including mainly Levofloxacin, Amoxicillin–clavulanic acid, Cefpodoxime, Ceftriaxone, Piperacillin/tazobactam, Cefoperazone-sulbactam.
********Mild: outpatients, Moderate: hospitalized patients (with or without supplemental oxygen), Severe: ICU added patients, non-invasive/invasive ventilation or ECMO required, patients
with acute respiratory distress syndrome (ARDS).
*********N is the total number of cases in each category; Chilblain-like lesions (110), Vesicular lesions (89), Urticaria-like lesions (89), Maculopapular lesions (223), Vascular lesions (55),
Miscellaneous (31), Total (597).

pro-inflammatory cytokines increase may result in a “cytokine
storm” which is an immune pathological condition (69–71).
Increased cytokines allow them to access the skin, where they
stimulate various cells, including lymphocytes, dendritic cells,
macrophages, neutrophils, monocytes, and Langerhans cells to
cause various skin manifestations (22, 69). Maybe a hyperviremia
state is responsible for vascular lesions in severe COVID-19
patients. We suggest further investigations on the viral load
levels among patients with vascular lesions compared with other
skin manifestations.
The antigen-antibody complex can lead to complement
activation and subsequent mast cell degranulation. This
mechanism is suggested particularly for the urticaria-like
lesions (43).
A low or delayed interferon response may result in
uncontrolled viral replication followed by a subsequent cytokine
storm which can lead to severe disease (72). Activation of the
host immune system in response to viral antigen deposition may
result in vascular damage in COVID-19 infection (73). It seems
that high levels of type 1 interferon response, a critical factor in
immunity against viral agents, is associated with chilblain-like
lesions and mild disease (15, 72, 74). Activation and aggregation
of cytotoxic CD8+ T cells and B cells also lead to lymphocytic
thrombophilic arteritis and destruction of keratinocytes (21, 22).
Nests of Langerhans cells are seen in most of the COVID-19
skin lesion biopsies and have been also reported in another
viral-induced skin dermatitis-like pytriasis rosea (75).
Coinfection with other viruses is another potential possibility
for COVID-19 related cutaneous manifestations. Some skin
lesions in COVID-19 patients are very similar to rashes induced
by other viruses like parvovirus18, herpes simplex virus type
1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), and
poxviruses, both clinically and histologically. It is probable that
because of the attenuation of the immune system, COVID-19
patients are susceptible to coinfection with or relapse of the
other viral exanthems. This hypothesis is strongly suggested
for vesicular and some miscellaneous lesions (e.g., erythema

The overall frequency of cutaneous manifestations in COVID19 patients was 5.95%, with a range from 0.2% up to 20.4% in
different studies (6, 65).
Although skin presentations of COVID-19 are well described,
the pathogenesis of skin lesions remains unknown. The direct
viral invasion of the skin cells may be one possibility.
Angiotensin-converting enzyme 2 (ACE2) is known as a ligand
for the Spike protein of SARS-CoV-2 for entering human cells
(66). There is a high expression of ACE2 on keratinocytes and
sweat gland cells, respectively (67, 68). Thus, SARS-CoV-2 can
directly infect keratinocytes resulting in necrosis. This hypothesis
is consistent with our histologic findings which demonstrated
the epidermal and adnexal necrosis in all skin lesions except
vesicular rashes. According to Amatore et al., neither viralinduced cytopathic alterations nor intranuclear inclusions were
seen in skin biopsies (35). However, SARS-CoV-2 spike and
envelope proteins were detected in the endothelial cells of
damaged skin in two cases with purpuric rashes (22). RT-PCR for
SARS-CoV-2 was performed on skin samples of some patients
and was negative in all of them. Since the nasopharyngeal swabs
of these patients were positive simultaneously, we assume that it
can be a false negative result due to a small viral load or technical
problems. Further research is urgently needed.
Skin lesions during SARS-CoV2 infection might be immunerelated phenomena. It has been shown that the presence of
virus RNA in blood is related to greater severity of infection
(69). Viremia is also associated with the levels of cytokines
and growth factors in a dose-dependent manner with markedly
higher levels in patients suffering from more severe COVID-19
(69). Recognition of the viral RNA by Toll-free receptors like
TLR7 stimulates the intracellular signaling pathways which in
turn enhance the cytokine secretion (69).
In a group of patients, with the end of the first week of the
infection, a sharp increase in inflammatory cytokines such as
interleukin (IL)1, IL2, IL7, IL10, granulocyte colony-stimulating
factor (G-CSF), tumor necrosis factor (TNF) α and interferon
(IFN)-g occurs. Overactivation of immune responses followed by
Frontiers in Medicine | www.frontiersin.org
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However, Robustelli et al. mentioned that the skin lesion
developed 3 weeks after discontinuation of the drug (42). As
a conclusion, most of our reviewed articles considered the
potential possibility of drug-induced exanthems but in almost
all cases, dermatologic manifestations preceded the drug intake
or the rashes disappeared despite the continuation of drugs
(5, 7, 16, 20, 23, 37, 42, 43). So it is very unlikely that
current COVID-19 medications are responsible for the reported
skin lesions.
In our study, the prevalence of comorbidities in COVID19 patients with skin manifestations is about 17.9% mainly
reported in patients with maculopapular lesions. History of
serious comorbidities like cardiovascular disease, hypertension,
and obstructive lung disease was mostly reported in patients
with vascular lesions; suggesting that patients with these skin
manifestations are more complicated cases and need more
attention. Interestingly, immune disorders were more common
in patients with chilblain-like lesions. This finding is not
reported yet and we suggest it to be focused on due to the
possible relationship with the etiology and pathophysiology of
these lesions.
Fever, cough, and dyspnea were more frequent in patients
with vascular lesions and less frequent in patients with chilblainlike lesions. Also, 17% of patients with chilblain-like lesions were
asymptomatic regarding systemic symptoms. Astonishingly,
headache, dysosmia/dysgeusia, nasal congestion/coryza,
and irritability/confusion were more common in patients
with vesicular lesions. This finding can demonstrate the
probable link between vesicular lesions and neurological
manifestations. Future investigations are required to clarify
the issue.

multiform) due to their unique histologic findings compared
to other skin lesions of COVID-19 (24, 32, 37). A study
reported four COVID-19 patients presenting diffuse vesicular
lesions which microbiological and serological investigations
demonstrated varicella infection (24). Thus, in COVID-19
patients with vesicular lesions, physicians need to investigate
other possible etiological factors other than SARS-CoV-2.
Coagulopathy and vasculitis are other possible reasons for
skin lesions during COVID-19. Evidence shows that COVID19 patients are predisposed to coagulopathy and subsequent
thrombotic events (76). It seems to be a result of inflammatory
cytokine release, hypoxia, and other illness or therapeutic risk
factors (76). Microvascular thrombosis of dermal vessels leads to
ischemia or vasculitis mainly seen in chilblain-like or vascular
lesions. Magro et al. focused on the role of the complement
factors activation, especially alternative and lectin pathways, and
subsequent thrombotic microvascular injuries (22). Evidence
for this hypothesis is the elevated levels of CH50, C3, and C4
in blood samples as well as significant vascular depositions of
C5b-9, C3d, and C4d in the dermis of skin specimens (22).
According to our histologic findings mentioned in RESULT,
vascular thrombosis was reported in almost all skin biopsies
(except vesicular lesions). This finding across with the increased
level of D-dimer, fibrinogen, and prolonged PT and INR in most
patients is in favor of this hypothesis. Another presentation of
coagulopathy in COVID-19 patients is hemorrhagic events and
subsequent dermatologic manifestations (petechiae, purpura,
and livedo). These manifestations are not specific to SARS-CoV2. Schneider et al. reported a petechial rash associated with
coronavirus NL63 (77, 78).
Extremely dilated blood vessels were introduced as a
diagnostic histological finding for SARS-CoV-2 by Zengarini
et al. (28). There are other reports of vasodilation and
telangiectatic vessels in the dermis. With this finding, Magro
et al. explained a possible pathway in which dysfunction of ACE2
(due to SARS-CoV-2 binding) and subsequent elevated level of
angiotensin2 can result in high activation of endothelial nitric
oxide synthase (eNOS) and ensuing vasodilation (22).
Drug-induced eruptions may occur during COVID-19.
COVID-19 patients usually use a set of medications that
potentially can cause cutaneous rashes. The current study
found that paracetamol, azithromycin, hydroxychloroquine,
lopinavir/ritonavir, and remdesivir were the most common
medications used for COVID-19 patients. Paracetamol has been
reported to cause asymmetrical drug-related intertriginous and
flexural exanthema (STRIFE) (16). However, in Mahé et al. study,
despite keeping the drug, skin lesions disappeared; that is very
uncommon in drug reactions (16). Najarian et al. mentioned
that maculopapular lesions of their patient could be according
to azithromycin use or hypersensitivity reaction to azithromycin
due to concurrent viral infection (20).
Hydroxychloroquine that has been used in 45% of all
the cases (mentioned in Result) is one of the most likely
medications to cause different skin rashes. Acute generalized
exanthematous pustulosis (AGEP), erythroderma, urticaria, and
erythema multiform are some of the skin lesions that have
been reported in connection with hydroxychloroquine (79–81).
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LIMITATIONS
There were limited articles that mentioned complete data about
all the items including the disease severity and outcome of the
COVID-19 patients with dermatologic presentations. Another
limitation was the absence of data about the COVID-19 patients
without skin manifestations. Future cohort studies are required
to compare the severity and prognosis of the disease in patients
with and without skin manifestations, considering other related
characteristics. Such studies help to better understand the
prognostic value of the cutaneous manifestations in COVID19 patients.

CONCLUSIONS
Cutaneous lesions occur most often in middle age individuals
at the same time or after the systemic symptoms of COVID-19.
Urticaria-like lesions commonly (47%) occurred at the same time
with other symptoms. It may suggest that urticaria-like lesions
may be a diagnostic sign for COVID-19. A maculopapular rash
is the main reported skin involvement in COVID-19 patients
and is associated with intermediate severity of the disease. The
mere occurrence of skin manifestations in COVID-19 patients
is not an indicator for the disease severity, and it highly
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depends on the type of skin lesions. Chilblain-like and vascular
lesions are the ends of a spectrum in which from chilblain-like
to vascular lesions, the severity of the disease increases, and
the patient’s prognosis worsens. We highly suggest emergency
and general practitioners to evaluate the suspected COVID-19
patients for any cutaneous manifestations. Those with vascular
lesions should also be considered as high-priority patients for
further medical care.
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